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Introduction. Splenic radiotherapy, applied at low doses in patients with symptomatic secondary organomegaly to myelo or
lymphoproliferative syndromes, is classically widely used treatment.
Objectives. To analyze the effectiveness of an easily applicable and reproducible technique based on the degree of palliation of
the clinical, and the toxicity proﬁle developed.
Methods. From 09/2007 to 12/2012, 7 consecutive patients were referred for abdominal palliative treatment. The age of all of
them exceeded the ﬁfth decade of life. They were diagnosed with idiophatic myeloﬁbrosis (1), essential thrombocythaemia (2),
non-Hodgkin mantle cell lymphoma (1), polycythaemia vera (2), and acute myeloid leukaemia (1). None of them were candidates
for splenectomy. It was applied as exclusive treatment in two patients, while the rest received further systemic treatment.
Three of the patients presented compressive symptoms such as dyspnea (1) or pseudo-occlusive symptoms (2) before beginning
radiotherapy. The prescribed dose was up to 2Gy in 0.25Gy fractions (two fractions per week). The plan was carried out by two
opposing ﬁelds-AP and PA-except for one single case in which three ﬁelds were used-one AP and two obliques. The sizes of said
ﬁelds ranged from 39×30 to 30×18 cm.
Results. After performing a variable follow-up with a range between 2 and 18 months, ﬁve of the patients achieved signiﬁcant
clinical improvement, leading to a reduction in dyspnea (1), reduction in abdominal circumference by ultrasound (2), and for
two of them it resulted in decisive therapy for the reintroduction of an oral diet due to the decompression of adjacent organs
(duodenum). Five patients showed depletion in one or more cell series: 4 thrombocytopenia, 2 anemia, 3 neutropenia.
Conclusion. Splenic radiotherapy, fractioned at low-dose, for hematological disorders that present secondary symptomatic
splenomegaly, is an effective, safe and easy technique, which contributes to the patient’s wellbeing and comfort.
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Introduction. About 50% of all cancer patients develop metastases. Radiation therapy has proven effective in bone and brain
metastases.
Objective. To analyze the variability of RT utilization rates in clinical practice in our region, and to estimate the irradiation rate.
Methods. Data were collected from all patients undergoing radiotherapy for bone and brain metastases during 2007 in the 12
public hospitals in Andalusia. Calculation of the rate of radiotherapy use was based on the cancer incidence and the number of
radiotherapy treatments for bone and brain metastases and all cancer sites as well as the review of the literature.
Results. In 2007, 9319 patients undergoing RT for cancer at any site, of which 1242 (79%) received radiotherapy for bone metastases
(n=744) or brain metastases (n=498). Lung, breast, prostate and digestive system were the most frequent primary tumours. No
signiﬁcant difference between bone metastases and brain metastases groups were observed in: characteristics of patients, mean
distance from hospital or time from consultation to radiohtearpy treatment. However, radiotherapy schedules differed among
hospitals and between patient groups: 10 × 300 cGy, 5 × 400 cGy and 1 × 800cGy were applied in 32, 27 and 25%, respectively,
of bone metastases patients, whereas 10 × 300cGy was used in 49% of brain metastases patients. It was estimated that 1576
patients should have been treated with RT for B and Br M. Thus, 1242 treated patients in our study represented 79% of these 1576
estimated patients
Conclusions. Differences in radiotherapy schedules among hospitals may reﬂect variability in clinical practice among the medical
teams. Palliative RT use in BM and BrM is high and close to the expected rate.
http://dx.doi.org/10.1016/j.rpor.2013.03.409
